Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial

Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial

Research on animal models of fragile X syndrome suggests that STX209, a γ-aminobutyric acid type B (GABA[subscript B]) agonist, might improve neurobehavioral function in affected patients. We evaluated whether STX209 improves behavioral symptoms of fragile X syndrome in a randomized, double-blind, p...

Full description

Bibliographic Details
Main Authors: Berry-Kravis, Elizabeth M., Hessl, David, Rathmell, Barbara, Zarevics, Peter, Cherubini, Maryann, Walton-Bowen, Karen, Mu, Yi, Nguyen, Danh V., Gonzalez-Heydrich, Joseph, Wang, Paul P., Carpenter, Randall L., Hagerman, Randi J., Bear, Mark
Other Authors: Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Format: Article
Language:en_US
Published: American Association for the Advancement of Science (AAAS) 2015
Online Access:http://hdl.handle.net/1721.1/95776

Internet

http://hdl.handle.net/1721.1/95776

Similar Items